###### Strengths and limitations of this study

-   Well-phenotyped cohort with lung function tests prior to exposure available.

-   Identification of a viable pulmonary artery to aorta (PA/A) ratio (0.92) as a biomarker associated with World Trade Center (WTC)-Lung Injury.

-   Identification of biomarkers predictive of PA/A vasculopathy.

-   Limited generalisability because of the unique WTC-related exposure.

-   Retrospective study design and logistic regression implies only associated findings, and does not reflect causality.

Background {#s1}
==========

Development of lung disease after the World Trade Center (WTC) exposure has been a common finding among exposed workers, volunteers and lower Manhattan residents. In rescue/recovery workers from the Fire Department of the City of New York (FDNY), WTC exposure led to WTC-Lung Injury (WTC-LI).[@R1] [@R2] Our group has previously defined WTC-LI as the chronic inflammatory lung dysfunction experienced by a subcohort of firefighters with intense exposure to WTC dust.[@R1] [@R2] It is characterised by primarily obstructive respiratory dysfunction with substantial and persistent losses in forced expiratory volume in 1 s (FEV~1~)% predicted to ≤77% in the subsequent 6.5 years postexposure. In addition, systemic biomarkers of inflammation, metabolic derangement and cardiovascular disease (CVD) predict WTC-LI.[@R2]

One of the hallmarks of particulate matter exposure is systemic inflammation, endothelial dysfunction and subsequent end-organ damage. High ambient particulate matter exposures significantly decrease FEV~1~ in a period as short as 5--7 days. Epidemiological investigation has documented associations between increased ambient particulates, lung disease and CVD. Systemic inflammation produces vascular endothelial injury and subsequent vascular disease. Recent studies associate systemic vascular involvement with lung disease and prospective studies have demonstrated an association between impaired lung function and central arterial stiffness even before the development of frank vascular disease, with systemic inflammation contributing to this association.[@R5]

Pulmonary vascular injury occurs early in smoking-related chronic obstructive pulmonary disease (COPD) with pulmonary perfusion abnormalities and reduced blood return to the heart is observed prior to development of WTC-LI.[@R8] A similar pathophysiology most likely occurs in irritant induced lung disease. Pulmonary arteriopathy was present in 58% of lung biopsies from non-FDNY-WTC exposed individuals and in 74% with constrictive bronchiolitis after inhalational exposures during military service in Iraq and Afghanistan.[@R11] [@R12] An increased ratio of the pulmonary artery to aorta (PA/A) diameter measured by CT has been associated with pulmonary hypertension and poor outcomes in various disease states. Additionally, an elevated PA/A has been associated with past and future exacerbations in patients with moderate-to-severe COPD.[@R13] The PA/A has been associated with a decreased FEV~1~ in the same population. Multiple serum biomarkers have been identified that predict vascular disease and several have been incorporated into clinical practice. To date, there have been no serum biomarkers identified that predict an enlarged PA/A in obstructive lung disease.

Utilising a nested case--control design, we investigated if an elevated PA/A was associated with WTC-LI in a population that also had serum biomarkers. We then determined the ability of vasoactive serum biomarkers drawn within 6 months of 9/11/2001 to predict the eventual development of an elevated PA/A.

Methods {#s2}
=======

Study design {#s2a}
------------

Annual physicals occurred prior to 9/11/2001, and active-duty firefighters had normal lung function testing, ECG assessment and measures of exercise capacity. Those with abnormal cardiopulmonary testing were placed on medical leave and were not part of the rescue and recovery efforts.

WTC exposed FDNY firefighters (N=1720) entered the FDNY-WTC Health Program and had spirometry at entry into medical monitoring as previously described.[@R1] Symptomatic participants referred for subspecialty pulmonary evaluation (SPE) between 10/1/2001 and 3/10/2008 underwent specialised pulmonary function testing as previously described.[@R1] Inclusion criteria were applied to the symptomatic cohort. In total, N=801/1720 (47%) were never-smokers, male, had reliable National Health and Nutrition Examination Survey (NHANES) normative data for the FEV~1~% predicted, entered FDNY-WTC Health Program within 200 days of 9/11/2001 and had pre-9/11 FEV~1~\>75% predicted. All participants signed an informed Institutional Review Board approved consent at the time of enrolment allowing analysis of their information and samples for research (Montefiore Medical Center; \#07-09-320 and New York University; \#11-00439).

FEV~1~% predicted at SPE was used as a measurable, phenotypic marker of WTC-LI. Cases represented those who had continued lung dysfunction that we termed WTC-LI, whereas controls represented those who did not have WTC-LI. Cases (N=100) were defined as being within one SD of the lowest FEV~1~% predicted of the cohort at SPE (FEV~1~≤77%). Controls (N=153) were those who had FEV~1~\>77% and were randomly selected after stratification based on body mass index (BMI) and FEV~1~ as previously defined.[@R1]

CT scans were administered as standard of care measures to the population, but only a subset was available at the single centre where this research was conducted. Serum biomarkers and CT scans were available for N=34/100 cases and N=63/153 controls ([figure 1)](#BMJOPEN2014005575F1){ref-type="fig"}. The population was then restratified by the PA/A ratio using a cut-off of 0.92 for analysis of biomarkers predictive of PA/A.

![Study design**.** Participants in the FDNY-WTC Health Program presented for pulmonary evaluation (SPE). The baseline cohort met the listed inclusion criteria. Cases (N=34) and controls (N=63) had CT and biomarkers available. A, aorta; FEV~1~, forced expiratory volume in 1 s; FDNY, Fire Department of the City of New York; WTC-LI, World Trade Center-Lung Injury; NHANES, National Health and Nutrition Examination Survey; NYU, New York University; PA, pulmonary artery; PFT, pulmonary function test.](bmjopen2014005575f01){#BMJOPEN2014005575F1}

Demographics {#s2b}
------------

Age, gender and years of service at FDNY were obtained from the FDNY-WTC Health Program database. Degree of exposure was self-reported at the first FDNY-WTC monitoring examination and was categorised using the FDNY-WTC Exposure Intensity Index (arrival time): present on the morning of 9/11/2001 or arrived after noon on 9/11/2001.[@R1] Those arriving after day 3 were excluded from the analysis as a result of their low numbers in this sample. Height and weight were measured at the SPE.

Lung function measures and CT {#s2c}
-----------------------------

Pulmonary function testing was performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines as described. The first available post-9/11 CT was retrieved for the 34 cases and 63 controls. Contrast studies and CT scans obtained after 2009 were not included. Bronchial wall thickening (BWT) and air trapping (AT) were previously assessed.[@R1] Inspiratory images, collected with a BF40 algorithm and viewed on standard mediastinal windows, were reviewed using iSite PACS (Philips iSite Enterprise, V.3.6.114; <http://www.healthcare.philips.com>). The diameter of the main PA at the level of its bifurcation and the diameter of the ascending A in its maximum dimension were recorded using the same image, online supplementary figure S1. The reader, trained by a board certified radiologist in this method, was blinded to the case status.[@R13] [@R14]

Serum sampling and analysis {#s2d}
---------------------------

Fasting blood was drawn at the first post-9/11 FDNY-WTC monitoring examination, processed and stored (Bio-Reference Laboratories, Inc, Elmwood Park, New Jersey, USA) as previously described.

The serum was analysed using a CVD-1(HCVD1-67AK) and a 39-Plex Human Pro-inflammatory Panel according to the manufacturer\'s instructions (Millipore, Billerica, Massachusetts, USA) on a Luminex 200IS (Luminex Corporation, Austin, Texas, USA).

Data were analysed with the MasterPlex QT software (V.1·2; MiraiBio, Inc). Each batch of the samples processed contained controls and cases in an approximate 12/7 ratio as previously described.[@R4]

Statistical analysis {#s2e}
--------------------

SPSS 20 (IBM, Armonk, New York, USA) and STATA V.12.1 (StataCorp LP, College Station, Texas, USA) were used for database management and statistics. Demographics, CT data and analyte levels were compared by the Student t test, Mann-Whitney U test and χ^2^ test where appropriate. The cut-off point of the PA/A ratio that maximised the value of the Youden index (sensitivity+specificity−1) was used for predicting the development of WTC-LI.[@R15] Logistic regression was used to first see if the PA/A ratio was a marker of WTC-LI. Then a separate logistic regression was used to analyse if serum biomarkers could predict the PA/A ratio. Variables identified as potential confounding factors in previous studies and those with a p\<0.20 in the univariable analysis were included in the multivariable logistic regression model. A backward stepwise approach was used to determine the most parsimonious model for the serum biomarkers, with a prespecified p\<0.10. Hosmer-Lemeshow\'s goodness-of-ﬁt test was used to assess calibration of the model. The model discrimination was evaluated through the receiver operating characteristic area under the curve (AUC). To test the robustness of the serum biomarker models, internal validation was performed using bootstrapping (10 000 bootstrap samples). Data are expressed as the mean (SD), median (IQR) or OR (95% CI), unless otherwise stated. A two-sided p value less than 0.05 was considered significant.

Results {#s3}
=======

Demographics of the case--control study {#s3a}
---------------------------------------

This case--control study was drawn from a population of 801 never-smokers with normal pre-9/11 lung function. In total, 253/801 individuals had serum available from their first post-9/11 monitoring examination. Non-contrast chest CT was available for review from 97 participants (34/100 cases and 63/153 controls). The demographics of individuals with available serum and CTs are summarised in [table 1](#BMJOPEN2014005575TB1){ref-type="table"}. The control and case groups had similar WTC exposure: time from 9/11 to the first post-9/11 monitoring examination, time from 9/11 to SPE, years of service and age at 9/11. BMI, body surface area (BSA) and height of cases were higher than controls at SPE.

###### 

Demographics, CT and pulmonary function test data

  Event              Measure                 Cases          N                   Controls       N         p Value
  ------------------ ----------------------- -------------- ------------------- -------------- --------- ---------
  Pre-9/11           FVC (%)                 84 (80--94)    34                  97 (89--111)   63        \<0.001
  FEV~1~ (%)         86 (82--95)             34             104 (93--114)       63             \<0.001   
  FEV~1~/FVC         84 (79--87)             34             85 (82--89)         63             0.960     
  At 9/11            Present at collapse\*   12 (35)        34                  18 (29)        63        0.494
  Arrived later\*    22 (65)                 34             45 (71)             63                       
  Years of service   15 (7--20)              34             13 (6--18)          63             0.317     
  SPE                9/11 to SPE (months)    34 (25--52)    34                  33 (24--57)    63        0.928
  FVC (%)            76 (72--86)             34             96 (90--104)        63             \<0.001   
  FEV~1~ (%)         72 (64--74)             34             96 (90--102)        63             \<0.001   
  FEV~1~/FVC         74 (65--78)             34             78 (75--82)         63             0.004     
  BD response        15 (6--25)              30             4 (1--9)            33             0.001     
  TLC (%)            86 (80--101)            28             105 (98--112)       32             \<0.001   
  FRC (%)            84 (76--100)            28             102 (91--109)       32             0.002     
  RV (%)             130 (107--145)          28             129 (115--141)      32             0.859     
  DL~CO~ (%)         95 (85--106)            27             106 (99--113)       31             0.006     
  BMI (kg/m^2^)      31 (29--34)             34             29 (27--31)         63             0.004     
  CT                 PA†                     29.22 (3.24)   34                  28.19 (3.23)   63        0.138
  A†                 32.09 (3.68)            34             31.95 (3.19)        63             0.850     
  PA/A†              0.92 (0.11)             34             0.89 (0.10)         63             0.151     
  PA/A≥0.92\*        18 (53)                 34             20 (32)             63             0.042     
  BWT\*              12 (36)                 33             21 (34)             61             0.851     
  Air trapping\*     19 (58)                 33             25 (41)             61             0.124     
  Age                47 (41--51)             34             46 (42--51)         63             0.791     
  Height (cm)        182 (178--183)          34             178 (173--183)      63             0.041     
  BSA (m^2^)         2.24 (2.17--2.43)       34             2.09 (2.01--2.28)   63             0.001     

Expressed as median (IQR) except \*Expressed as N (%), †Expressed as mean (SD). A, aorta; BSA, body surface area; BD, bronchodilator; BMI, body mass index; BWT, bronchial wall thickening; DL~CO~, diffusion capacity of the lung for carbon monoxide; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; FRC, functional residual capacity; PA, pulmonary artery; RV, residual volume; SPE, pulmonary evaluation; TLC, total lung capacity.

Lung function {#s3b}
-------------

Cases had a lower FEV~1~ than controls at pre-9/11 and at SPE ([table 1)](#BMJOPEN2014005575TB1){ref-type="table"}. Cases also had a lower FEV~1~/forced vital capacity (FVC) ratio, total lung capacity, functional residual capacity and diffusion capacity of the lung for carbon monoxide at SPE. Cases had an increased bronchodilator response. At pre-9/11 testing, the FEV~1~/FVC ratio was similar. FEV~1~ in cases and controls declined from pre-9/11 to SPE (104--96% and 86--72%, respectively; p\<0.001 all comparisons). FVC demonstrated a similar pattern. To confirm that the median FEV~1~ difference represented individual changes, we used patients as their own controls. The mean ratio of FEV~1~ was 0.92 vs 0.77 in controls versus cases, respectively, between pre-9/11 and SPE testing, p\<0.001, demonstrating a significantly greater loss of lung function in cases as compared with controls, even when analysed individually.

CT scan measurements {#s3c}
--------------------

PA and A measurements on available CTs from cases and controls are outlined in [table 1](#BMJOPEN2014005575TB1){ref-type="table"}. The PA diameter was modestly correlated with BSA and BMI (r=0.219, 0.265; p=0.031, 0.009, respectively), but did not vary with height or age. The A diameter demonstrated modest correlation with age and BMI (r=0.376, 0.284; p\<0.001, 0.005, respectively). The measured PA/A declined with increased age (r=−0.256, p=0.011) but was not significantly associated with height, BSA or BMI, which is similar to reported associations in a larger cohort study.[@R16] The mean PA/A in cases was 0.92, similar to the 90% upper limit of normal in the Framingham Heart Study.[@R16] Cases had similar proportions of AT and BWT to controls.

PA/A as a biomarker of WTC-LI {#s3d}
-----------------------------

After calculating the Youden index, a PA/A value of 0.92 was selected as the cut-off for predicting the development of WTC lung injury in a logistic regression analysis. After adjusting for age at CT, pre-9/11 FEV~1~, BMI at SPE and exposure, the odds of having a low FEV~1~ at SPE in patients with a value of PA/A≥0.92 were 4.02 (95% CI 1.21 to 13.41; p=0.023) times larger than the odds of those patients with a value \<0.92 (AUC=0.854 (95% CI 0.773 to 0.934); Hosmer-Lemeshow\'s p=0.55).

Vascular disease biomarkers and PA/A association {#s3e}
------------------------------------------------

CT measurements across the PA/A of 0.92 are displayed in online supplementary table S1. There were 38 individuals with a ratio ≥0.92 and 59 with a ratio \<0.92. There was a higher proportion of measured BWT in the low ratio group. There was a similar amount of AT in both groups. Age and time since 9/11 were similar in both groups. Height, age, BSA, BMI and exposure intensity were similar across the PA/A ratio of 0.92 (data not shown).

Levels of analytes across the ratio of 0.92 are displayed in [table 2](#BMJOPEN2014005575TB2){ref-type="table"}. The results of multivariable logistic analysis using the backward stepwise approach are shown in [table 3](#BMJOPEN2014005575TB3){ref-type="table"}. For each 1 ng/mL increase of serum macrophage derived chemokine (MDC), the odds of having a subsequent PA/A ratio ≥0.92 increased by 2.08-fold (95% CI 1.05 to 4.11). For each 10 ng/mL increase in soluble endothelial selectin (sE-selectin) and total plasminogen activator inhibitor 1 (tPAI-1), the odds of having a PA/A ratio ≥0.92 increased by 33% (95% CI 6% to 68%) and decreased by 12% (95% CI 2% to 21%), respectively.

###### 

Biomarker PA/A relationship

  -----------------------------------------------------------------------
  Analyte\      PA/A                    p Value                   
  ng/mL                                                           
  ------------- ----------------------- ------------------------- -------
  MDC           1.51 (1.21--2.01)       1.41 (0.99--1.77)         0.101

  Adiponectin   12 770 (9510--20 941)   13 218 (10 037--18 537)   0.789

  sE-selectin   49.7 (36.5--63.2)       42.8 (35.3--56.1)         0.153

  tPAI-1        119.8 (84.5--152.4)     139.7 (119.5--173.3)      0.057

  MMP-9         345.7 (265.8--465.3)    352.4 (267.9--517.9)      0.949

  MPO           141.0 (104.3--226.1)    135.3 (95.1--289.0)       0.865

  sICAM-1       165.2 (130.4--197.4)    157.8 (136.1--201.8)      0.952

  sVCAM-1       1355 (1119--1679)       1335 (1108--1602)         0.617
  -----------------------------------------------------------------------

Values expressed as median (IQR). MDC, macrophage derived chemokine; MMP, matrix metalloproteinase; MPO, myeloperoxidase; sE-selectin, soluble endothelial selectin; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule; tPAI, total plasminogen activator inhibitor.

###### 

Serum biomarker models predicting pulmonary artery/aorta ≥0.92

  Model           Analytes              Crude                 Adjusted\*                                  
  --------------- --------------------- --------------------- --------------------- --------------------- -------
  Univariable     MDC                   1.70 (0.90 to 3.19)   0.100                 1.78 (0.93 to 3.37)   0.080
  sE-selectin     1.18 (0.97 to 1.44)   0.093                 1.20 (0.98 to 1.47)   0.075                 
  tPAI-1          0.92 (0.84 to 1.01)   0.093                 0.93 (0.85 to 1.03)   0.148                 
  Multivariable   MDC                   1.99 (1.02 to 3.88)   0.043                 2.08 (1.05 to 4.11)   0.036
  sE-selectin     1.32 (1.05 to 1.65)   0.018                 1.33 (1.06 to 1.68)   0.016                 
  tPAI-1          0.87 (0.78 to 0.97)   0.013                 0.88 (0.79 to 0.98)   0.024                 

Per 1 ng/mL MDC, per 10 ng/mL sE-selectin, tPAI-1.

X2 (5)=15.69, p=0.008. Hosmer--Lemeshow\'s goodness-of-fit test p=0.25.

Area under the receiver operating characteristic curve=0.728 (0.623--0.834).

\*Adjusted for age at the CT and exposure group. MDC, macrophage derived chemokine; sE-selectin, soluble endothelial selectin; tPAI, total plasminogen activator inhibitor.

The probability of having a PA/A ratio ≥0.92 was determined for each of our three analytes when holding all other variables in the model constant ([figure 2)](#BMJOPEN2014005575F2){ref-type="fig"}. The probability increased from 0.21 to 0.79 as the concentration of MDC increased from 0.2 to 4.41 ng/mL ([figure 2](#BMJOPEN2014005575F2){ref-type="fig"}A). The probability of an increased PA/A increased from 0.14 to 0.75 as the concentration of sE-selectin increased from 12.7 to 125.4 ng/mL ([figure 2](#BMJOPEN2014005575F2){ref-type="fig"}B). An increase in the concentration of tPAI-1 from 41.4 to 288.9 ng/mL decreased the probability of having an increased PA/A ratio from 0.63 to 0.11 ([figure 2](#BMJOPEN2014005575F2){ref-type="fig"}C). When using biomarkers to predict WTC-LI, MDC remains significant with an OR of 2.1, data not shown. However, sE-selectin and tPAI-1 were not significant predictors of WTC-LI.

![Probability plots. Probability of having pulmonary artery/aorta (PA/A) ratio≥0.92 over the range of macrophage derived chemokine (MDC) (A), soluble endothelial selectin (sE-selectin) (B) and total plasminogen activator inhibitor 1 (tPAI-1) (C) are represented when adjusting for the covariates of exposure, and age. Plots express probability isopleths for the development of World Trade Center-Lung Injury (forced expiratory volume in 1 s loss) with all other covariates held constant.](bmjopen2014005575f02){#BMJOPEN2014005575F2}

Discussion {#s4}
==========

We have identified that biomarkers of cardiovascular risk, inflammation and metabolic syndrome expressed within 6 months of 9/11/2001 predict the development of WTC-LI. Vascular changes occur early in COPD, prior to the development of WTC-LI.[@R10] In a recently published analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE)/COPDGene cohorts, in patients with moderate-to-severe disease, a PA/A\>1 was significantly associated with COPD exacerbations.[@R13] A unique advantage to observing the PA/A ratio by non-contrast CT is that it is a non-invasive mechanism that provides insight into the pulmonary and systemic circulation.[@R17] [@R18]

In this nested case--control study of our well-phenotyped WTC exposed FDNY cohort, we found that an elevated PA/A≥0.92 was associated with an observed development of WTC-LI, with odds of 4.02. Early levels of MDC, sE-selectin and tPAI-1 showed the ability to predict PA/A≥0.92.

Recently, CT measurements of the PA/A have been associated with outcomes other than pulmonary hypertension. The ECLIPSE/COPDGene cohort examined patients with advanced disease, many requiring supplemental O~2~.[@R13] Although our cohort\'s mean PA and A were similar to those measured in the ECLIPSE/COPDGene, 81% of the cohort did not meet the GOLD COPD criteria. Therefore, it was expected that the PA/A would be less than the previously reported ratios of 1. When comparing our cohort with the Framingham Heart Study, we found that our case mean PA/A and PA values are similar to their 90% upper limit of normal. Although we found a similar inverse relationship with PA/A and age, there were only weak associations with height and BSA.[@R16] In a very recent study, an abnormal PA/A has been associated with increased mortality in patients with coronary artery disease.[@R19] Our study would indicate that abnormalities in the PA/A may represent a marker of early vascular injury in particulate matter-related lung disease and is in line with these recent publications.

BWT was also found to be more prevalent in those with PA/A≥0.92. Our previous work has linked this indicator of proximal airway inﬂammation and/or remodelling with WTC-LI.[@R1] Our new finding may show that BWT is related to early vascular changes. However, it is unclear what the temporal relationship is between BWT and vascular changes.

Our group and others have linked biomarkers of systemic inflammation and vascular disease with COPD. The proposed pathobiological mechanism of this relationship is related to inflammatory loss of lung parenchyma and vascular beds. COPD is a systemic process affecting not only the airways but also the lung parenchyma, vascular structures and other organ systems such as skeletal muscle and adipose tissue.[@R20] Non-invasive biomarkers guiding management and prognostication in COPD are needed.[@R21] [@R22]

We chose to study a limited number of biologically plausible vasoactive biomarkers, to examine the link between their expression in a serum soon after massive particulate matter exposure and PA/A. MDC, also known as CCL22, is an inflammatory mediator that has been linked to obstructive lung dysfunction by our laboratory and others.[@R23] It is important in platelet activation and has been associated with a systemic vascular phenomenon.[@R24] [@R25] sE-selectin is a member of the selectin family of carbohydrate binding lectins, and is specifically produced by activated endothelial cells.[@R26] It is one of the main endothelial neutrophil adhesion molecules and has been linked to poor CVD outcomes. Additionally, well-known metabolic risk factors for CVD are associated with an increase in the soluble form sE-selectin.[@R27] [@R28] tPAI-1, the main inhibitor of the plasminogen activator, has been associated with lung diseases,[@R29] atherosclerosis, thrombosis and vascular remodelling.[@R30] It has been analysed in pulmonary hypertension and right heart failure, although whether it is inhibitory or stimulatory in these disease states has yet to be elucidated and is under investigation.[@R33] [@R34]

In our population, we found that elevated levels of MDC, sE-selectin were significantly associated with an increased PA/A ratio. tPAI-1 was inversely related to this ratio. These associations correlate with previous reports on CVD. This association is novel because it is the first time these biomarkers have been associated with a non-invasive marker of vascular injury in lung disease. However, in using biomarkers to predict WTC-LI, only MDC remained a predictive biomarker. This may indicate that sE-selectin and tPAI-1 may be involved with vascular remodelling after exposure, but may not be directly relate to the lung damage seen in those with WTC-LI. The population size may also have limited the ability to find significant differences in the two groups.

There are several limitations to this study. Understandably, this cohort of FDNY firefighters did not have pre-exposure serum banked for future analyses. We did achieve the next best option by obtaining serum samples within a few months postexposure. There were no unexposed or asymptomatic exposed controls in our study. Replication of these findings in other populations with and without particulate matter exposure will be important. We were able to obtain CT images on only 97 participants with the available serum. We do not have longitudinal follow-up data (FEV~1~, CTs, serum biomarkers) for additional correlation. Finally, we have no data on the prevalence of important comorbidities such as sleep apnoea, left heart failure and thromboembolic disease in this population. Thus, the finding linking an elevated PA/A to a decreased FEV~1~ may be influenced by the presence of these unaccounted for confounders.

In this nested case-cohort study, we were able to identify cardiovascular-related serum biomarkers drawn within 6 months of 9/11/2001 that predicted an abnormal PA/A ratio. The observation that biomarkers predict changes in PA/A and that PA/A was a non-invasive marker lung injury (FEV~1~ loss) in this postexposure population provides a novel association with well-characterised processes in vascular biology and inflammation secondary to particulate matter exposure. Importantly, these biomarkers were expressed during the early stages of WTC lung injury and reflect potential processes leading to disease susceptibility. This insight on protein expression and its relationship to FEV~1~ loss and vascular injury may guide future mechanistic and therapeutic studies in the field.
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